

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – September 9, 2020 @ 4:00pm

OHCA Webinar

Register for the meeting here:

<https://odot.webex.com/odot/onstage/g.php?MTID=ea903ae9549435eccc589a619e6d9cfc3>

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Skrepnek

Telephone Conference Participants

DUR Board Members:

Dr. Stephen Anderson –
Dr. Jennifer de los Angeles –
Ms. Jennifer Boyett –
Dr. Markita Broyles –
Dr. Theresa Garton –
Dr. Megan Hanner –
Dr. Lynn Mitchell –
Dr. John Muchmore –
Dr. Lee Muñoz –
Dr. James Osborne –

participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference
participating via Webex Teleconference

Public Access to Meeting via Webex:

Register at:

<https://odot.webex.com/odot/onstage/g.php?MTID=ea903ae9549435eccc589a619e6d9cfc3>

Or join by phone:

Dial: +1-415-655-0002

Event number: 133 711 6718

Event password: 20200909

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting www.okhca.org/DUR and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. July 8, 2020 DUR Minutes – Vote
- B. July 8, 2020 DUR Recommendations Memorandum

Items to be presented by Dr. Chandler, Dr. Travers, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Academic Detailing Program Update – See Appendix B

- A. Pharmacy Helpdesk Activity for July 2020
- B. Medication Coverage Activity for July 2020
- C. Pharmacy Helpdesk Activity for August 2020
- D. Medication Coverage Activity for August 2020
- E. Academic Detailing Program Update

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Tramadol 100mg Tablet – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Baxley, Dr. Borders, Dr. Schmidt, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Koselugo™ (Selumetinib), Pemazyre™ (Pemigatinib), and Qinlock™ (Ripretinib) – See Appendix D

- A. Introduction
- B. Product Summaries
- C. Recommendations

Items to be presented by Dr. Baxley, Dr. Borders, Dr. Schmidt, Dr. Muchmore, Chairman:

7. Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Enhertu® (Fam-Trastuzumab Deruxtecan-nxki), Phesgo™ (Pertuzumab/Trastuzumab/Hyaluronidase-zzxf), Trodelvy™ (Sacituzumab Govitecan), and Tukysa™ (Tucatinib) – See Appendix E

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Breast Cancer Medications
- D. Prior Authorization of Breast Cancer Medications
- E. Market News and Updates
- F. Product Summaries
- G. Recommendations
- H. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Baxley, Dr. Borders, Dr. Schmidt, Dr. Muchmore, Chairman:

8. Annual Review of Prostate Cancer Medications and 30-Day Notice to Prior Authorize Rubraca® (Rucaparib) – See Appendix F

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Prostate Cancer Medications
- D. Prior Authorization of Prostate Cancer Medications
- E. Market News and Updates
- F. Rubraca® (Rucaparib) Product Summary
- G. Recommendations
- H. Utilization Details of Prostate Cancer Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

9. Annual Review of Sickle Cell Disease (SCD) Medications and 30-Day Notice to Prior Authorize Adakveo® (Crizanlizumab-tmca), Oxbryta® (Voxelotor), and Reblozyl® (Luspatercept-aamt) – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of SCD Medications
- C. Prior Authorization of SCD Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of SCD Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Annual Review of Synagis® (Palivizumab) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Synagis® (Palivizumab)
- C. Prior Authorization of Synagis® (Palivizumab)
- D. Season Comparison
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

11. Annual Review of Givlaari® (Givosiran) and Scenesse® (Afamelanotide) – See Appendix I

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Givlaari® (Givosiran) and Scenesse® (Afamelanotide)
- D. Prior Authorization of Givlaari® (Givosiran) and Scenesse® (Afamelanotide)
- E. Market News and Updates
- F. College of Pharmacy Recommendations
- G. Utilization Details of Givlaari® (Givosiran) and Scenesse® (Afamelanotide)

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

12. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix J

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

13. Future Business* (Upcoming Product and Class Reviews)

- A. Cystic Fibrosis Medications
- B. Hepatitis C Medications
- C. Spinal Muscular Atrophy (SMA) Medications
- D. Ovarian Cancer Medications

**Future business subject to change.*

14. Adjournment